These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33554047)

  • 1. Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance.
    Thier B; Paschen A
    Cell Stress; 2021 Jan; 5(2):26-28. PubMed ID: 33554047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
    Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
    J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
    Stupia S; Heeke C; Brüggemann A; Zaremba A; Thier B; Kretz J; Sucker A; Philip M; Zelinskyy G; Ferrone S; Roesch A; Horn S; Hadaschik E; Schadendorf D; Trilling M; Dittmer U; Griewank K; Zhao F; Paschen A
    Clin Cancer Res; 2023 Aug; 29(15):2894-2907. PubMed ID: 37199727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
    Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
    Pérez-Núñez I; Rozalén C; Palomeque JÁ; Sangrador I; Dalmau M; Comerma L; Hernández-Prat A; Casadevall D; Menendez S; Liu DD; Shen M; Berenguer J; Ruiz IR; Peña R; Montañés JC; Albà MM; Bonnin S; Ponomarenko J; Gomis RR; Cejalvo JM; Servitja S; Marzese DM; Morey L; Voorwerk L; Arribas J; Bermejo B; Kok M; Pusztai L; Kang Y; Albanell J; Celià-Terrassa T
    Nat Cancer; 2022 Mar; 3(3):355-370. PubMed ID: 35301507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
    Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
    Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
    Gong X; Karchin R
    Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.
    Wickenhauser C; Bethmann D; Kappler M; Eckert AW; Steven A; Bukur J; Fox BA; Beer J; Seliger B
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.
    Sadagopan A; Michelakos T; Boyiadzis G; Ferrone C; Ferrone S
    JAMA Oncol; 2022 Mar; 8(3):462-473. PubMed ID: 34940799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
    Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
    EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
    Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
    Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
    Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
    Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility antigens and antigen-processing molecules in uveal melanoma.
    Krishnakumar S; Abhyankar D; Sundaram AL; Pushparaj V; Shanmugam MP; Biswas J
    Clin Cancer Res; 2003 Sep; 9(11):4159-64. PubMed ID: 14519640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RIG-I activation is critical for responsiveness to checkpoint blockade.
    Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
    Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
    Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
    J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications.
    Hargadon KM
    Br J Dermatol; 2021 Dec; 185(6):1095-1104. PubMed ID: 34185875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Pai SI; Jack Lee J; Carey TE; Westra WH; Ferrone S; Moore C; Mosunjac MB; Shin DM; Ferris RL;
    Oral Oncol; 2018 Feb; 77():92-97. PubMed ID: 29362132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.